153 related articles for article (PubMed ID: 27376027)
1. Hypothesis: The Intratumoral Immune Response against a Cancer Progenitor Cell Impacts the Development of Well-Differentiated versus Dedifferentiated Disease in Liposarcoma.
Tseng WW; Chopra S; Engleman EG; Pollock RE
Front Oncol; 2016; 6():134. PubMed ID: 27376027
[TBL] [Abstract][Full Text] [Related]
2. Genomic profiling of dedifferentiated liposarcoma compared to matched well-differentiated liposarcoma reveals higher genomic complexity and a common origin.
Beird HC; Wu CC; Ingram DR; Wang WL; Alimohamed A; Gumbs C; Little L; Song X; Feig BW; Roland CL; Zhang J; Benjamin RS; Hwu P; Lazar AJ; Futreal PA; Somaiah N
Cold Spring Harb Mol Case Stud; 2018 Apr; 4(2):. PubMed ID: 29610390
[TBL] [Abstract][Full Text] [Related]
3. Analysis of the intratumoral adaptive immune response in well differentiated and dedifferentiated retroperitoneal liposarcoma.
Tseng WW; Malu S; Zhang M; Chen J; Sim GC; Wei W; Ingram D; Somaiah N; Lev DC; Pollock RE; Lizée G; Radvanyi L; Hwu P
Sarcoma; 2015; 2015():547460. PubMed ID: 25705114
[TBL] [Abstract][Full Text] [Related]
4. Dedifferentiation within well-differentiated liposarcoma of the extremity or trunk: Implications for clinical management.
Tseng WW; Barretta F; Baia M; Barisella M; Radaelli S; Callegaro D; Yoon DH; Fiore M; Gronchi A
J Surg Oncol; 2021 Oct; 124(5):838-845. PubMed ID: 34254688
[TBL] [Abstract][Full Text] [Related]
5. Resectable well-differentiated versus dedifferentiated liposarcomas: two different diseases possibly requiring different treatment approaches.
Lahat G; Anaya DA; Wang X; Tuvin D; Lev D; Pollock RE
Ann Surg Oncol; 2008 Jun; 15(6):1585-93. PubMed ID: 18398663
[TBL] [Abstract][Full Text] [Related]
6. Second Primary Malignancies in Patients with Well-differentiated/Dedifferentiated Liposarcoma.
Jung E; Fiore M; Gronchi A; Grignol V; Pollock RE; Chong SS; Chopra S; Hamilton AS; Tseng WW
Anticancer Res; 2018 Jun; 38(6):3535-3542. PubMed ID: 29848707
[TBL] [Abstract][Full Text] [Related]
7. Myogenic differentiation and histologic grading are major prognostic determinants in retroperitoneal liposarcoma.
Gronchi A; Collini P; Miceli R; Valeri B; Renne SL; Dagrada G; Fiore M; Sanfilippo R; Barisella M; Colombo C; Morosi C; Stacchiotti S; Casali PG; Dei Tos AP; Pilotti S
Am J Surg Pathol; 2015 Mar; 39(3):383-93. PubMed ID: 25581729
[TBL] [Abstract][Full Text] [Related]
8. The prognostic impact of dedifferentiation in retroperitoneal liposarcoma: a series of surgically treated patients at a single institution.
Mussi C; Collini P; Miceli R; Barisella M; Mariani L; Fiore M; Casali PG; Gronchi A
Cancer; 2008 Oct; 113(7):1657-65. PubMed ID: 18704991
[TBL] [Abstract][Full Text] [Related]
9. Computed tomography scan-driven selection of treatment for retroperitoneal liposarcoma histologic subtypes.
Lahat G; Madewell JE; Anaya DA; Qiao W; Tuvin D; Benjamin RS; Lev DC; Pollock RE
Cancer; 2009 Mar; 115(5):1081-90. PubMed ID: 19156920
[TBL] [Abstract][Full Text] [Related]
10. Clinico-molecular study of dedifferentiation in well-differentiated liposarcoma.
Shimoji T; Kanda H; Kitagawa T; Kadota K; Asai R; Takahashi K; Kawaguchi N; Matsumoto S; Hayashizaki Y; Okazaki Y; Shinomiya K
Biochem Biophys Res Commun; 2004 Feb; 314(4):1133-40. PubMed ID: 14751251
[TBL] [Abstract][Full Text] [Related]
11. Distinct mdm2/p53 expression patterns in liposarcoma subgroups: implications for different pathogenetic mechanisms.
Pilotti S; Della Torre G; Lavarino C; Di Palma S; Sozzi G; Minoletti F; Rao S; Pasquini G; Azzarelli A; Rilke F; Pierotti MA
J Pathol; 1997 Jan; 181(1):14-24. PubMed ID: 9071998
[TBL] [Abstract][Full Text] [Related]
12. Immunoreactivity of p53, mdm2, and p21WAF1 in dedifferentiated liposarcoma: special emphasis on the distinct immunophenotype of the well-differentiated component.
Adachi T; Oda Y; Sakamoto A; Saito T; Tamiya S; Masuda K; Tsuneyoshi M
Int J Surg Pathol; 2001 Apr; 9(2):99-109. PubMed ID: 11484509
[TBL] [Abstract][Full Text] [Related]
13. MRI Differential Diagnosis and Guidance for Puncture Biopsy of Musculoskeletal Dedifferentiated Liposarcoma and Well Differentiated Liposarcoma.
Zhang T; Liu B
Cancer Manag Res; 2024; 16():455-463. PubMed ID: 38774493
[TBL] [Abstract][Full Text] [Related]
14. IGF2BP3 as a Prognostic Biomarker in Well-Differentiated/Dedifferentiated Liposarcoma.
Klingbeil KD; Tang JP; Graham DS; Lofftus SY; Jaiswal AK; Lin TL; Frias C; Chen LY; Nakasaki M; Dry SM; Crompton JG; Eilber FC; Rao DS; Kalbasi A; Kadera BE
Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760460
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of Replication-Dependent Histone Signifies a Subset of Dedifferentiated Liposarcoma with Increased Aggressiveness.
Yoo Y; Park SY; Jo EB; Choi M; Lee KW; Hong D; Lee S; Lee CR; Lee Y; Um JY; Park JB; Seo SW; Choi YL; Kim S; Lee SG; Choi M
Cancers (Basel); 2021 Jun; 13(13):. PubMed ID: 34206586
[TBL] [Abstract][Full Text] [Related]
16. Well-differentiated liposarcoma (atypical lipomatous tumors).
Laurino L; Furlanetto A; Orvieto E; Dei Tos AP
Semin Diagn Pathol; 2001 Nov; 18(4):258-62. PubMed ID: 11757865
[TBL] [Abstract][Full Text] [Related]
17. Dedifferentiated liposarcoma: a clinicopathological analysis of 155 cases with a proposal for an expanded definition of dedifferentiation.
Henricks WH; Chu YC; Goldblum JR; Weiss SW
Am J Surg Pathol; 1997 Mar; 21(3):271-81. PubMed ID: 9060596
[TBL] [Abstract][Full Text] [Related]
18. Significance of loss of heterozygosity of the RB1 gene during tumour progression in well-differentiated liposarcomas.
Schneider-Stock R; Boltze C; Jaeger V; Stumm M; Seiler C; Rys J; Schütze K; Roessner A
J Pathol; 2002 Aug; 197(5):654-60. PubMed ID: 12210086
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive adipocytic and neurogenic tissue microarray analysis of NY-ESO-1 expression - a promising immunotherapy target in malignant peripheral nerve sheath tumor and liposarcoma.
Shurell E; Vergara-Lluri ME; Li Y; Crompton JG; Singh A; Bernthal N; Wu H; Eilber FC; Dry SM
Oncotarget; 2016 Nov; 7(45):72860-72867. PubMed ID: 27655679
[TBL] [Abstract][Full Text] [Related]
20. Targeting CDK4 (cyclin-dependent kinase) amplification in liposarcoma: A comprehensive review.
Assi T; Kattan J; Rassy E; Nassereddine H; Farhat F; Honore C; Le Cesne A; Adam J; Mir O
Crit Rev Oncol Hematol; 2020 Sep; 153():103029. PubMed ID: 32593094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
